Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 3 - Gonadal dysgenesis: ovarian function and reproductive health in Turner syndrome


1. Nielsen J, Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet. 1991;87:81–3.
2. Turner HH. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology. 1938;23:566–74.
3. Ullrich O. Über typische Kombinationsbilder multipler Abartungen. Z Kinderheilk. 1930;49:271–6.
4. Ferguson-Smith MA. Karyotype-phenotype correlations in gonadal dysgenesis and their bearing on the pathogenesis of malformations. J Med Genet. 1965;2:142–55.
5. Ross JL, Scott C Jr, Marttila P, et al. Phenotypes associated with SHOX deficiency. J Clin Endocrinol Metab. 2001;86:5674–80.
6. Maraschio P, Tupler R, Barbierato L, et al. An analysis of Xq deletions. Hum Genet. 1996;97:375–81.
7. Nicolaides KH, Azar G, Snijders RJ, et al. Fetal nuchal oedema: associated malformations and chromosomal defects. Fetal Diagn Ther. 1992;7:123–31.
8. Bronshtein M, Zimmer EZ, Blazer S. A characteristic cluster of fetal sonographic markers that are predictive of fetal Turner syndrome in early pregnancy. Am J Obstet Gynecol. 2003;188:1016–20.
9. Ruiz C, Lamm F, Hart PS. Turner syndrome and multiple-marker screening. Clin Chem. 1999;45:2259–61.
10. Gunther DF, Eugster E, Zagar AJ, et al. Ascertainment bias in Turner syndrome: new insights from girls who were diagnosed incidentally in prenatal life. Pediatrics. 2004;114:640–4.
11. Koeberl DD, McGillivray B, Sybert VP. Prenatal diagnosis of 45, X/46, XX mosaicism and 45, X: implications for postnatal outcome. Am J Hum Genet. 1995;57:661–6.
12. Hook EB, Warburton D. The distribution of chromosomal genotypes associated with Turner’s syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Hum Genet. 1983;64:24–7.
13. Baena N, De Vigan C, Cariati E, et al. Turner syndrome: evaluation of prenatal diagnosis in 19 European registries. Am J Med Genet A. 2004;129:16–20.
14. Hamamy HA, Dahoun S. Parental decisions following the prenatal diagnosis of sex chromosome abnormalities. Eur J Obstet Gynecol Reprod Biol. 2004;116:58–62.
15. Hall S, Abramsky L, Marteau TM. Health professionals’ reports of information given to parents following the prenatal diagnosis of sex chromosome anomalies and outcomes of pregnancies: a pilot study. Prenat Diagn. 2003;23:535–8.
16. Warburton D, Kline J, Stein Z, et al. Monosomy X: a chromosomal anomaly associated with young maternal age. Lancet. 1980;1:167–9.
17. Sutton EJ, McInerney-Leo A, Bondy CA, et al. Turner syndrome: four challenges across the lifespan. Am J Med Genet A. 2005;139:57–66.
18. Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet. 1977;29:94–7.
19. Wiktor AE, Van Dyke DL. Detection of low level sex chromosome mosaicism in Ullrich-Turner syndrome patients. Am J Med Genet A. 2005;138:259–61.
20. Palmer CG, Reichman A. Chromosomal and clinical findings in 110 females with Turner syndrome. Hum Genet. 1976;35:35.
21. Nishi MY, Domenice S, Medeiros MA, et al. Detection of Y-specific sequences in 122 patients with Turner syndrome: nested PCR is not a reliable method. Am J Med Genet. 2002;107:299–305.
22. Cools M, Drop SL, Wolffenbuttel KP, et al. Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev. 2006;27:468–84.
23. Brant WO, Rajimwale A, Lovell MA, et al. Gonadoblastoma and Turner syndrome. J Urol. 2006;175(5):1858–60.
24. Landin-Wilhelmsen K, Bryman I, Hanson C, et al. Spontaneous pregnancies in a Turner syndrome woman with Y-chromosome mosaicism. J Assist Reprod Genet. 2004;21:229–30.
25. Salo P, Kaariainen H, Petrovic V, et al. Molecular mapping of the putative gonadoblastoma locus on the Y chromosome. Genes Chromosomes Cancer. 1995;14:210–14.
26. Tsuchiya K, Reijo R, Page DC, et al. Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. Am J Hum Genet. 1995;57:1400–7.
27. Gravholt CH, Juul S, Naeraa RW, et al. Prenatal and postnatal prevalence of Turner’s syndrome: a registry study. BMJ. 1996;312:16–21.
28. Hreinsson JG, Otala M, Fridstrom M, et al. Follicles are found in the ovaries of adolescent girls with Turner’s syndrome. J Clin Endocrinol Metab. 2002;87:3618–23.
29. Meng H, Hager K, Rivkees SA, et al. Detection of Turner syndrome using high-throughput quantitative genotyping. J Clin Endocrinol Metab. 2005;90:3419–22.
30. Wolff DJ, Van Dyke DL, Powell CM. Laboratory guideline for Turner syndrome. Gene Med. 2010;12:52–5.
31. Rivkees S, Hager K, Hosono S, et al. A highly sensitive, high-throughput assay for the detection of Turner syndrome. J Clin Endocrinol Metb. 2011;96(3):699–705.
32. Loscalzo ML, Van PL, Ho VB, et al. Association between fetal lymphedema and congenital cardiovascular defects in Turner syndrome. Pediatrics. 2005;115:732–5.
33. Berdahl LD, Wenstrom KD, Hanson JW. Web neck anomaly and its association with congenital heart disease. Am J Med Genet. 1985;56:304–7.
34. Gotzsche C, Krag-Olsen B. Prevalence of cardiovascular malformations and association with karyotypes in Turner’s syndrome. Arch Dis Child. 1994;71:433–6.
35. Mazzanti L, Prandstraller D, Tassinari D, et al. Heart disease in Turner’s syndrome. Helv Paediatr Acta. 1998;43:25–31.
36. Volkl TM, Degenhardt K, Koch A, et al. Cardiovascular anomalies in children and young adults with Ullrich-Turner syndrome: the Erlangen experience. Clin Cardiol. 2005;28:88–92.
37. Chalard F, Ferey S, Teinturier C, et al. Aortic dilatation in Turner syndrome: the role of MRI in early recognition. Pediatr Radiol. 2005;35:323–6.
38. Castro AV, Okoshi K, Ribeiro SM, et al. Cardiovascular assessment of patients with Ullrich-Turner’s syndrome on Doppler echocardiography and magnetic resonance imaging. Arq Bras Cardiol. 2002;78:51–8.
39. Dawson-Falk KL, Wright AM, Bakker B, et al. Cardiovascular evaluation in Turner syndrome: utility of MR imaging. Australas Radiol. 1992;36:204–9.
40. Ho VB, Bakalov VK, Cooley M, et al. Major vascular anomalies in Turner syndrome: prevalence and magnetic resonance angiographic features. Circulation. 2004;110:1694–700.
41. Ostberg JE, Brookes JAS, McCarthy C, et al. A comparison of echocardiography and magnetic resonance imaging in cardiovascular screening of adults with Turner syndrome. J Clin Endocrinol Metab. 2004;89:5966–71.
42. Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998;101:E11.
43. Lin AE, Lippe B, Rosenfeld RG. Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics. 1998;102:E12.
44. Elsheikh M, Casadei B, Conway GS, et al. Hypertension is a major risk factor for aortic root dilatation in women with Turner’s syndrome. Clin Endocrinol (Oxf). 2001;54:69–73.
45. Bechtold SM, Dalla Pozza R, Becker A, et al. Partial anomalous pulmonary vein connection: an underestimated cardiovascular defect in Ullrich–Turner syndrome. Eur J Pediatr. 2004;163:158–62.
46. Shiroma K, Ebine K, Tamura S, et al. A case of Turner’s syndrome associated with partial anomalous pulmonary venous return complicated by dissecting aortic aneurysm and aortic regurgitation. J Cardiovasc Surg (Torino). 1997;38:257–9.
47. van Wassenaer AG, Lubbers LJ, Losekoot G. Partial abnormal pulmonary venous return in Turner syndrome. Eur J Pediatr. 1988;148:101–3.
48. Ostberg JE, Donald AE, Halcox JPJ, et al. Vasculopathy in Turner syndrome: arterial dilatation and intimal thickening without endothelial dysfunction. J Clin Endocrinol Metab. 2005;90:5161–6.
49. Baguet JP, Douchin S, Pierre H, et al. Structural and functional abnormalities of large arteries in Turner syndrome. Heart. 2005;91:1442–6.
50. Bondy CA, Van PL, Bakalov VK, et al. Prolongation of the cardiac QTc interval in Turner syndrome. Medicine (Baltimore). 2006;85:75–81.
51. Liao AW, Snijders R, Geerts L, et al. Fetal heart rate in chromosomally abnormal fetuses. Ultrasound Obstet Gynecol. 2000;16:610–3.
52. Gravholt CH, Hansen KW, Erlandsen M, et al. Nocturnal hypertension and impaired sympathovagal tone in Turner syndrome. J Hypertens. 2006;24:353–60.
53. Mazzanti L, Cacciari E. Congenital heart disease in patients with Turner’s syndrome. Italian Study Group for Turner syndrome (ISGTS). J Pediatr. 1998;133:688–92.
54. Nathwani NC, Unwin R, Brook CG, et al. The influence of renal and cardiovascular abnormalities on blood pressure in Turner syndrome. Clin Endocrinol (Oxf). 2000;52:371–7.
55. Gravholt CH, Naeraa RW, Nyholm B, et al. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome. The impact of sex hormone replacement. Diabetes Care. 1998;21:1062–70.
56. Radetti G, Crepaz R, Milanesi O, et al. Cardiac performance in Turner’s syndrome patients on growth hormone therapy. Horm Res. 2001;55:240–4.
57. Sas TC, Cromme-Dijkhuis AH, de Muinck Keizer-Schrama SM, et al. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner’s syndrome. Dutch Working Group on Growth Hormone. J Pediatr. 1999;135:470–6.
58. Bondy CA, Van PL, Bakalov VK, et al. Growth hormone treatment and aortic dimensions in Turner syndrome. J Clin Endocrinol Metab. 2006;91:1785–8.
59. van den Berg J, Bannink EM, Wielopolski PA, et al. Aortic distensibility and dimensions and the effects of growth hormone treatment in the Turner syndrome. Am J Cardiol. 2006;97:1644–9.
60. Roman MJ, Devereux RB, Kramer-Fox R, et al. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol. 1989;64:507–12.
61. Nathwani NC, Unwin R, Brook CG, et al. Blood pressure and Turner syndrome. Clin Endocrinol (Oxf). 2000;52:363–70.
62. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan’s syndrome. N Engl J Med. 1994;330:1335–41.
63. Karnis MF, Zimon AE, Lalwani SI, et al. Risk of death in pregnancy achieved through oocyte donation in patients with Turner syndrome: a national survey. Fertil Steril. 2003;80:498–501.
64. Ranke MB, Pfluger H, Rosendahl W, et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr. 1983;141:81–8.
65. Rongen-Westerlaken C, Corel L, van de, Broeck J, et al. Reference values for height, height velocity and weight in Turner’s syndrome. Swedish Study Group for GH treatment. Acta Paediatr. 1997;86:937–42.
66. Gravholt CH, Weis Naeraa R. Reference values for body proportions and body composition in adult women with Ullrich-Turner syndrome. Am J Med Genet. 1997;72:403–8.
67. Binder G, Fritsch H, Schweizer R, et al. Radiological signs of Leri-Weill dyschondrosteosis in Turner syndrome. Horm Res. 2001;55:71–6.
68. Elder DA, Roper MG, Henderson RC, et al. Kyphosis in a Turner syndrome population. Pediatrics. 2002;109:e93.
69. Kim JY, Rosenfeld SR, Keyak JH. Increased prevalence of scoliosis in Turner syndrome. J Pediatr Orthop. 2001;21:765–6.
70. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, et al. A longitudinal study on bone mineral density until adulthood in girls with Turner’s syndrome participating in a growth hormone injection frequency-response trial. Clin Endocrinol (Oxf). 2000;52:531–6.
71. Stahnke N, Keller E, Landy H, et al. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J Pediatr Endocrinol Metab. 2002;15:129–38.
72. Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child. 1985;60:932–5.
73. Davenport ML, Punyasavatsut N, Stewart PW, et al. Growth failure in early life: an important manifestation of Turner syndrome. Horm Res. 2002;57:157–64.
74. The Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian Randomized Controlled Trial. J Clin Endocrinol Metab. 2005;90:3360–6.
75. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003;88:1119–25.
76. Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr. 1998;132:319–24.
77. Rosenfeld RG, Frane J, Attie KM, et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr. 1992;121:49–55.
78. Pasquino AM, Pucarelli I, Segni M, et al. Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group. J Endocrinol Invest. 2005;28:350–6.
79. Ranke MB, Lindberg A, Chatelain P, et al. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J Clin Endocrinal Metab. 2000;85:4212–18.
80. Reiter EO, Blethen SL, Baptista J, et al. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner’s syndrome. J Clin Endocrinol Metab. 2001;86:1936–41.
81. Quigley CA, Crowe BJ, Anglin DG, et al. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87:2033–41.
82. Carel JC, Mathivon L, Gendrel C, et al. Growth hormone therapy for Turner syndrome: evidence for benefit. Horm Res. 1997;48:31–4.
83. Sas TC, de Muinck K, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999;84:4607–12.
84. Hofman P, Cutfield WS, Robinson EM, et al. Factors predictive of response to growth hormone therapy in Turner’s syndrome. J Pediatr Endocrinol Metab. 1997;10:27–33.
85. Davenport ML, Quigley CA, Bryant CG, et al. A Effect of early growth hormone (GH) treatment in very young girls with Turner syndrome (TS). Seventh Joint European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society Meeting, Lyon, France, 2005.
86. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab. 2000;85:769–75.
87. Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res. 2004;62(Suppl 1):59–65.
88. Boechat MI, Westra SJ, Lippe B. Normal US appearance of ovaries and uterus in four patients with Turner’s syndrome and 45, X karyotype. Pediatr Radiol. 1996;26:37–9.
89. Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G. Spontaneous pubertal development in Turner’s syndrome. J Clin Endocrinol Metab. 1997;82:1810–13.
90. Hovatta O. Pregnancies in women with Turner’s syndrome. Ann Med. 1999;31:106–10.
91. Chernausek SD, Attie KM, Cara JF, et al. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. J Clin Endocrinol Metab. 2000;85:2439–45.
92. Rosenfield RL, Devine N, Hunold JJ, et al. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab. 2005;90:6424–30.
93. Carel JC, Ecosse E, Bastie-Sigeac I, et al. Quality of life determinants in young women with Turner’s syndrome after growth hormone treatment: results of the StaTur population-based cohort study. J Clin Endocrinol Metab. 2005;90:1992–7.
94. Hogler W, Briody J, Moore B, et al. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy x-ray absorptiometry. J Clin Endocrinol Metab. 2004;89:193–9.
95. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner’s syndrome. N Engl J Med. 2011;364:1230–42.
96. Ankarberg-Lindgren C, Elfving M, Wikland KA, et al. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab. 2001;86:3039–44.
97. Soriano-Guillen L, Coste J, Ecosse E, et al. Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab. 2005;90:5197–204.
98. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003;88:1119–25.
99. Elsheikh M, Conway GS, Wass JA. Medical problems in adult women with Turner’s syndrome. Ann Med. 1999;31:99–105.
100. Gravholt CH, Juul S, Naeraa RW, et al. Morbidity in Turner syndrome. J Clin Epidemiol. 1998;51:147–58.
101. Price WH, Clayton JF, Collyer S, et al. Mortality ratios, life expectancy, and causes of death in patients with Turner’s syndrome. J Epidemiol Community Health. 1986;40:97–102.
102. Swerdlow AJ, Hermon C, Jacobs PA, et al. Mortality and cancer incidence in phromosome abnormalities: a cohort study. Ann Hum Genet. 2001;65:177–88.
103. Hultcrantz M. Ear and hearing problems in Turner’s syndrome. Acta Oto-Laryngol. 2003;123:253–7.
104. Elsheikh M, Conway GS. The impact of obesity on cardiovascular risk factors in Turner’s syndrome. Clin Endocrinol (Oxf). 1998;49:447–50.
105. Gravholt CH, Naeraa RW, Fisker S, et al. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner’s syndrome, with important modulations by treatment with 17β-estradiol. J Clin Endocrinol Metab. 1997;82:2570–7.
106. Gravholt CH, Lauridsen AL, Brixen K, et al. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome: a cross-sectional study. J Clin Endocrinol Metab. 2002;87:2798–808.
107. Landin-Wilhelmsen K, Bryman I, Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab. 2001;86:4166–70.
108. Elsheikh M, Hodgson HJ, Wass JA, et al. Hormone replacement therapy may improve hepatic function in women with Turner’s syndrome. Clin Endocrinol (Oxf). 2001;55:227–31.
109. Roulot D, Degott C, Chazouilleres O, et al. Vascular involvement of the liver in Turner’s syndrome. Hepatology. 2004;39:239–47.
110. Landin-Wilhelmsen K, Bryman I, Windh M, et al. Osteoporosis and fractures in Turner syndrome: importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf). 1999;51:497–502.
111. Bakalov V, Chen M, Baron J, et al. Bone mineral density and fractures in Turner syndrome. Am J Med. 2003;115:257–62.
112. Bechtold S, Rauch F, Noelle V, et al.Musculoskeletal analyses of the forearm in young women with Turner syndrome: a study using peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2001;86:5819–23.
113. Bakalov VK, Axelrod L, Baron J, et al. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2003;88:5717–22.
114. Bakalov VK, Cooley MM, Quon MJ, et al. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab. 2004;89:3516–20.
115. Cooley M, Bakalov V, Bondy CA. Lipid profiles in women with 45, X vs 46, XX primary ovarian failure. JAMA. 2003;290:2127–8.
116. Van PL, Bakalov VK, Bondy CA. Monosomy for the X chromosome is associated with an atherogenic lipid profile. J Clin Endocrinol Metab. 2006;91:2867–70.
117. Hojbjerg Gravholt C, Svenstrup B, Bennett P, et al. Reduced androgen levels in adult Turner syndrome: influence of female sex steroids and growth hormone status. Clin Endocrinol (Oxf). 1999;50:791–800.
118. Gravholt CH, Naeraa RW, Nyholm B, et al. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome. The impact of sex hormone replacement. Diabetes Care. 1998;21:1062–70.
119. Nathwani NC, Unwin R, Brook CG, et al. Blood pressure and Turner syndrome. Clin Endocrinol (Oxf). 2000;52:363–70.
120. Bonamico M, Pasquino AM, Mariani P, et al. Prevalence and clinical picture of celiac disease in Turner syndrome. J Clin Endocrinol Metab. 2002;87:5495–8.
121. Gravholt CH, Hansen KW, Erlandsen M, et al. Nocturnal hypertension and impaired sympathovagal tone in Turner syndrome. J Hypertens. 2006;24:353–60.
122. Hanton L, Axelrod L, Bakalov V, et al. The importance of estrogen replacement in young women with Turner syndrome. J Womens Health (Larchmt). 2003;12:971–7.
123. Weiss L. Additional evidence of gradual loss of germ cells in the pathogenesis of streak ovaries in Turner’s syndrome. J Med Genet. 1971;8(4):540–4.
124. Reynaud K, Cortvrindt R, Verlinde F, et al. Number of ovarian follicles in human fetuses with the 45, X karyotype. Fertil Steril. 2004;81(4):1112–19.
125. Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec. 1965;155:369.
126. Speed RM. The possible role of meiotic pairing anomalies in the atresia of human fetal oocytes. Hum Genet. 1988;78:260.
127. Bergeron L, Perez GI, Macdonald G, et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Gene Dev. 1998;12:1304.
128. Hreinsson JG, Otala M, Fridström M, et al. Follicles are found in the ovaries of adolescent girls with Turner’s syndrome. J Clin Endocrinol Metab. 2002;87(8):3618–23.
129. Borgström B, Hreinsson J, Rasmussen C, et al. Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles. J Clin Endocrinol Metab. 2009;94(1):74–80. Erratum in: J Clin Endocrinol Metab. 2009;94(4):1478.
130. Hagen CP, Aksglaede L, Sørensen K, et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–10.
131. Martin JR, Patrizio P. Options for fertility preservation in pediatric populations undergoing cancer chemotherapy. Pediatr Endocrinol Rev. 2009;6(Suppl 2):306–14.
132. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831–41.
133. Huang JY, Tulandi T, Holzer H, et al. Cryopreservation of ovarian tissue and in vitro matured oocytes in a female with mosaic Turner syndrome: case report. Hum Reprod. 2008;23:336–9.
134. Kavoussi SK, Fisseha S, Smith YR, et al. Oocyte cryopreservation in a woman with mosaic Turner syndrome: a case report. J Reprod Med. 2008;53:223–6.
135. Oktay K, Rodriguez-Wallberg KA, Sahin G. Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure. Fertil Steril. 2010;94(2):753.e15–19.
136. Hovatta O. Pregnancies in women with Turner’s syndrome. Ann Med. 1999;31(2):106–10.
137. Bryman I, Sylvén L, Berntorp K, et al. Pregnancy rate and outcome in Swedish women with Turner syndrome. Fertil Steril. 2011;95(8):2507–10.
138. Yaron Y, Ochshorn Y, Amit A, et al. Patients with Turner’s syndrome may have an inherent endometrial abnormality affecting receptivity in oocyte donation. Fertil Steril. 1996;65(6):1249–52.
139. Foudila T, Soderstrom-Anttila V, Hovatta O. Turner’s syndrome and pregnancies after oocyte donation. Hum Reprod. 1999;14:532–5.
140. Khastgir G, Abdalla H, Thomas A, et al. Oocyte donation in Turner’s syndrome: an analysis of the factors affecting the outcome. Hum Reprod. 1997;12(2):279–85.
141. McDonnell CM, Coleman L, Zacharin MR. A 3-year prospective study to assess uterine growth in girls with Turner’s syndrome by pelvic ultrasound. Clin Endocrinol (Oxf). 2003;58(4):446–50.
142. Bannink EM, van Sassen C, van Buuren S, et al. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. Clin Endocrinol (Oxf). 2009;70(2):265–73.
143. Taboada M, Santen R, Lima J, et al. Pharmacokinetics and pharmacodynamics of oral and transdermal 17{beta} estradiol in girls with Turner syndrome. J Clin Endocrinol Metab. 2011;96:3502–10.
144. Sheffer-Mimouni G, Mashiach S, Dor J, et al. Factors influencing the obstetric and perinatal outcome after oocyte donation. Hum Reprod. 2002;17(10):2636–40.
145. Chevalier N, Letur H, Lelannou D, et al. Materno-fetal cardiovascular complications in Turner syndrome after oocyte donation: insufficient prepregnancy screening and pregnancy follow-up are associated with poor outcome. J Clin Endocrinol Metab. 2011;96(2):E260–7.
146. Carlson M, Silberbach M. Dissection of the aorta in Turner syndrome: two cases and review of 85 cases in the literature. J Med Genet. 2007;44(12):745–9.
147. Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner syndrome. Circulation. 2007;116(15):1663–70.
148. Boissonnas CC, Davy C, Bornes M, et al. Careful cardiovascular screening and follow-up of women with Turner syndrome before and during pregnancy is necessary to prevent maternal mortality. Fertil Steril. 2009;91(3):929.e5–7.
149. Chalas Boissonnas C, Davy C, Marszalek A, et al. Cardiovascular findings in women suffering from Turner syndrome requesting oocyte donation. Hum Reprod. 2011;26(10):2754–62.
150. Bondy CA; Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92(1):10–25.
151. Hagman A, Källén K, Barrenäs ML, et al. Obstetric outcomes in women with Turner karyotype. J Clin Endocrinol Metab. 2011;96:3475–82.
152. Hadnott TN, Gould HN, Gharib AM, et al. Outcomes of spontaneous and assisted pregnancies in Turner syndrome: the U.S. National Institutes of Health experience. Fertil Steril. 2011;95(7):2251–6.